J. Thromb. Thrombolysis 2020 Feb 01
Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience.
Porfidia A, Agostini F, Giarretta I, Tonello D, Pastori D, Pignatelli P, Santoliquido A, Sartori M, Lessiani G, Visonà A, Donadini MP, Pola R
Upper-extremity deep vein thrombosis (UEDVT) accounts for about 5-10% of all cases of deep vein thrombosis (DVT). It is often associated with cancer a ...
Read More
Source: PubMed
Am. J. Med. 2020 Jan 30
Association of Reversal of Anticoagulation Preoperatively on 30-Day Mortality and Outcomes for Hip Fracture Surgery.
Yoo MS, Zhu S, Jiang SF, Hammer HL, McBride WJ, McCarthy CM, Green CE, Ananias MP
Hip fracture is common in the elderly, many of whom are on anticoagulation. However, data are limited on outcomes with anticoagulation reversal in pat ...
Read More
Source: PubMed
J. Heart Lung Transplant. 2020 Jan 21
Use of direct oral anticoagulants after heart transplantation.
Henricksen EJ, Tremblay-Gravel M, Moayedi Y, Yang W, Lee R, Ross HJ, Hiesinger W, Teuteberg JJ, Khush KK
Read More
Source: PubMed
Eur. Heart J. 2020 Feb 01
Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
Huang HK, Liu PP, Hsu JY, Lin SM, Peng CC, Wang JH, Loh CH
To evaluate the fracture risk among patients with atrial fibrillation (AF) treated with non-vitamin K antagonist oral anticoagulants (NOACs) or warfar ...
Read More
Source: PubMed
Bull Cancer 2020 Jan 28
[Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?]
Debourdeau P, Cossou-Gbeto C, Takam-Sohwe T, Laroche JP
According to international clinical practice guidelines, low-molecular-weight heparins are advocate for the treatment and the prevention of cancer ass ...
Read More
Source: PubMed
